Clinically, these findings indicate that early PTSD interventions might target UCHL1-related pathways to mitigate anhedonia and diurnal variation, while patients with chronic PTSD may benefit from strategies addressing SUMO1 and CX3CL1 to manage persistent anhedonia, potentially through anti-inflammatory or neuroprotective approaches. Here, SUMO1 is linked to post-traumatic stress disorder.